global teams

Cutting Edge Information recently conducted research among pharmaceutical medical affairs groups that looked at physician-interaction database ownership.  The research revealed that ownership of these databases varies among the surveyed companies.  Global groups...

Over the past few years, political, social and economic upheavals worldwide have thrust change on the life sciences landscape — and forced pricing teams to work overtime.  Today, these teams must deal with a series of events and trends that each have some effect...

Growing up, siblings have an unspoken rule that  if one received something or was allowed to do something that another wasn’t, instantly, life became “unfair” for the other party.  The smaller the age differential between the siblings, the more unfair the...

A recent study on medical science liaison (MSL) teams analyzes the global expansion of this key slice of medical affairs operations. Until recently, pharmaceutical and medical device companies have largely focused their MSL teams on the US market, with a small...

Our recent research suggests intensifying competition among pharmaceutical companies for capable regulatory affairs employees. In fact, experienced regulatory affairs personnel can be counted as a white hot commodity right now. Executives that I have talked with...

Traditionally, health outcomes liaisons (HOLs) and medical science liaisons (MSLs) represent two different areas of expertise. Both jobs serve an important role: to provide an educational connection between industry leaders and key stakeholders. The former serves...

Significant changes to medical science liaisons’ roles and expectations in the past 15 years have underscored the value MSLs bring to their organizations. MSLs not only provide access to highly influential physicians and medical researchers, but they also bring...

More regulations, more problems. It’s not exactly a catchphrase yet, but it is something you might have overheard within a pharmaceutical regulatory affairs office over the past several years. The simple fact is that over the past five to ten years, guidances...

Compliance is a necessary part of doing business (very necessary for bio/pharm), but sometimes it goes a shade too far. When asked what single factor he would change about compliance efforts at his company if he could, a compliance executive from a top pharma company...

By Shaylyn Pike, Senior Research Analyst Pharmaceutical companies' global clinical development strategies are diverse, but there are some points of agreement: clinical trials in emerging markets are more successful when companies hire local expertise....